A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Summary

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

Timeline

Start

2023-09-08

Primary completion

2024-11-19

Completion

2024-11-19

Outcome

Met primary endpoint

release “showing that immunobridging was established in the CANOPY clinical trial.” invivyd.com ↗

Publications

• Yalcin I, Hu L, West B, Narayan K, Holmes A, Wingertzahn MA. A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19. Infect Dis Ther. 2026 Apr;15(4):1007-1017. doi: 10.1007/s40121-026-01315-6. Epub 2026 Feb 16.
• Wolfe CR, Cohen J, Mahoney K, Holmes A, Betancourt N, Gupta D, Tosh K, Narayan K, Campanaro E, Katz C, Phelan AM, Yalcin I, Wingertzahn M, Hawn P, Schmidt P, Li Y, Popejoy M. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clin Infect Dis. 2025 Oct 6;81(3):439-450. doi: 10.1093/cid/ciaf265.

Drugs

Indications